Background: Mutation of the p53 tumor suppressor gene (also known as TP53) often leads to the synthesis of p53 protein that has a longer than normal half-life. Mutant p53 protein that accumulates in tumor cell nuclei can be detected by means of immunohistochemical staining techniques. Serum antibodies directed against p53 protein (p53-Abs) have been detected in some cancer patients. Purpose: We assayed serum samples from 80 patients with head and neck squamous cell carcinoma (HNSCC) for the presence of p53-Abs, and we evaluated potential associations between the presence of these antibodies and other histopathologic and clinical features. Methods: Serum was collected from each patient at the time of diagnosis. In addition, tumor biopsy specimens were obtained before the initiation of treatment. An enzyme-linked immunosorbent assay was used to detect p53-Abs. The accumulation of p53 protein in tumor cell nuclei was assessed immunohistochemically by use of the anti-p53 monoclonal antibody DO7. Patient treatment consisted of radiotherapy alone, primary chemotherapy followed by radiotherapy, or surgery and postoperative radiotherapy. Relapse-free and overall survival from the beginning of treatment were estimated by use of the Kaplan-Meier method; survival comparisons were made by use of the logrank statistic. Univariate and multivariate analyses were conducted
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Conclusions and Implications: The proportion of patients with HNSCC who have serum p53-Abs is smaller than that of patients exhibiting tumor cell accumulation of p53 protein. The presence of p53-Abs is significantly associated with increased risks of relapse and death. [J Natl Cancer Inst 1996;88:1228-33]
Alteration of the p53 tumor suppressor gene (also known as TP53) is probably one of the most common genetic features of human cancer (/), and it is detected in a wide variety of cancer types. Indeed, mutations in the p53 gene, studied by DNA sequencing, have been reported in 53%-93% of head and neck squamous cell carcinomas (HNSCCs) and cell lines (2) (3) (4) (5) (6) (7) (8) . Since most p53 mutations lead to the synthesis of stabilized protein that has a much longer half-life than that observed for wild-type p53 protein, it is possible to study the accumulation of mutated, inactive p53 protein by use of immunohistochemical techniques (9-11). Watling et al. (9) have reported that 62% of the tumor specimens examined in a series of HNSCCs exhibited p53 protein accumulation, which is comparable to the frequency of p53 gene mutation reported by others for this type of cancer. Furthermore, a strong correlation between p53 gene mutation and p53 protein accumulation has been reported for HNSCC (4) .
The clinical significance of p53 gene alterations in HNSCC is currently under investigation. Some studies (5) (6) (7) (8) (9) (10) (11) (12) have found that p53 mutation appears to be associated with shorter relapse-free and overall survival. However, this issue is controversial, since other studies have not found an association between p53 gene mutation and/or protein accumulation and poor clinical outcome (4, (13) (14) (15) (16) .
Accumulation of mutant p53 protein can lead to the production of anti-p53 antibodies (p53-Abs), according to reports of serologic analyses of patients with Burkitt's lymphoma (17); leukemia (18); and lung (19-21), breast (19, 22, 23) , liver (24), pancreatic (25, 26) , colon (27) , and ovarian (28) carcinomas. Two serologic studies (28, 29) conducted with more than 1000 patients who had various types of cancer have shown a strong correlation between the presence of p53-Abs and the frequency of p53 mutations in tumors. No p53-Abs have been found in cancer-free individuals. p53-Abs have been shown to recognize immunodominant epitopes in the carboxyl-and amino-terminal domains of the p53 polypeptide; these epitopes do not correspond to mutational hot spots (J9,30). This pattern of immune response is comparable to that found in animals hyperimmunized with human p53 protein {31), and the presence of p53-Abs has been postulated to be a consequence of the accumulation of mutant p53 protein in tumor cells.
p53-Abs were reported in 17% of the patients in a series of 41 individuals with HNSCC (52). In addition, a strong association was found between the presence of p53-Abs and poor clinical outcome in patients with breast cancer (33) . These results prompted us to look for serum p53-Abs in a larger series of patients with HNSCC and to evaluate whether associations existed between the presence of these antibodies and other histopathologic or clinical features of the patients, as well as with p53 protein accumulation in their tumors.
Materials and Methods

Patients and Treatment
From December 1991 through June 1992, 80 consecutive patients with nonmetastatic HNSCC were entered in the study. The mean age of the patients was 63 years (standard deviation [SD] = 10.1); 86% were male. The distribution of the patients according to their primary tumor sites and TNM (tumor, node, metastasis) classification (International Union Against Cancer, fourth edition, 1992) is reported in Table 1 . Patients were treated following standard protocols at our institution. Individuals with superficial T1-T2 tonsilar, laryngeal, or hypopharyngeal tumors underwent conventional radiotherapy alone, consisting of 70 Gy delivered in fractions of 2 Gy per day 5 days per week over a 7week period (34) . Patients with the most advanced oropharyngeal T4 tumors were treated with accelerated radiotherapy (35) . Patients with N3 disease were treated with primary chemotherapy (a total of three cycles, administered at 3-week intervals; each cycle consisted of cisplatin on day 1 at 100 mg/m and fluorouracil on days 1-5 at 1000 mg/m 2 per day) (36) followed by conventional radiotherapy (70 GyP weeks). Patients with the following carcinomas were offered surgery and postoperative radiotherapy if an operation was technically feasible and if the patients were physically fit for such an intervention: 1) tumors of the junction, anterior pillar, and base of the tongue if they were greater than 3 cm in diameter or deeply infiltrating; 2) tumors of the posterior wall if less than 4 cm in diameter; and 3) T3 and T4 laryngeal and hypopharyngeal tumors.
Overall survival and relapse-free survival were estimated from the beginning of treatment by use of the Kaplan-Meier method. Survival curves were compared by use of the logrank test (37) . The Wilcoxon rank test was used for determining whether T and N had the same location parameters in the groups defined according to p53-Ab status. Fisher's exact test (38) was used to test the independence of p53-Ab detection and other parameters. The mean follow-up period was 21 months (SD = 9.9). The factors associated with relapse-free and overall survival were evaluated first in univariate analysis and second in multivariate analysis with a forward stepwise Cox regression model. Survival analyses were performed using the SAS software package (SAS Institute, Inc., Cary, NC). All reported P values are two-sided.
Detection of p53-Abs and Immunostaining of p53 Protein in Tumors
Histology and immunohistochemistry. A tumor biopsy specimen was obtained from each patient before treatment. After fixing the specimen with acetic acid (5% vol/vol), formaldehyde (2% vol/vol), and ethyl alcohol (25% vol/vol), it was embedded in paraffin wax blocks and cut into 4-(im sections, which were mounted on coated slides (LLR3+; CML, Nemours, France). One section was stained with hematoxylin-eosin-safran and used for the diagnosis of epithelial tumor histologic type and for an evaluation of the tumor proportions that contained normal and necrotic tissue. Entire slides were evaluated microscopically, and benign tissue was also inspected for p53 immunoreactivity. Weak positive staining was observed in some cells of the proliferating basal and suprabasal layers of normal epithelium; however, this weak staining was not considered to be positive in our analysis. Determinations of p53 positivity were based on the presence of strong nuclear staining in tumor cells, as previously reported (13). Three degrees of p53 overexpression were defined arbitrarily according to the proportion of tumor nuclei that were strongly stained: low, less than or equal to 15%; intermediate, between 15% and 85%; and high, 85% or more.
pS3-Abs assay. Serum was collected at the time of diagnosis and was stored at -20 °C. The specificity and sensitivity of measuring p53-Abs as an indirect assay for p53 gene alterations has been described extensively (21282939). Using a new enzyme-linked immunosorbent assay (ELISA), we previously analyzed sera from more than 1000 patients with various types of cancer and from healthy blood donors; in that study, we demonstrated that p53-Abs are detected only in cancer patients and are strictly related to the occurrence of p53 mutations (29) . With the use of various immunologic approaches, these antibodies were shown unambiguously to be directed against human p53 protein (29) .
The major sites of antigen recognition by p53-Abs detected in human serum and by those produced experimentally in immunized animals are the amino-and carboxyl-terminal segments of the protein (40) . This epitope restriction has been demonstrated by binding sera to a series of 77 overlapping peptides that encompass the entire p53 molecule. The majority (98%) of positive sera reacted with an amino-terminal peptide, and 48% reacted with a carboxyl-terminal peptide (40) . Therefore, in the present study, sera were tested in an ELISA that employed five peptides as follows: 1) EPPLSQETFSDLWKLLPENNVLSPL; 2) DDL-MLSPDDIEQWFT; 3) SPDDIEQWFTEDPGP; 4) EALELKDAQAGKEPGGSRAHSSHLK; and 5) §p53-Abs = anti-p53 antibodies. IIModel (stepwide procedure) does not provide P values in the multivariate analysis for nodal stage, PS, and tumor stage (after stratification by treatment) because they did not reach the . 1 level. NS = not significant. GSRAHSSHLKSKKGQSTSRHKKLMF. Peptides 1, 2, and 3 are amino-terminal peptides, and peptides 4 and 5 are carboxyl-terminal peptides. These peptides correspond to peptides of Lubin et al. (40) as follows: 1 = 3, 4, and 5 in (40); 2 = 9 in (40); 3 = 10 in (40); 4 = 70, 71, and 72 in (40); and 5 = 73, 74, and 75 in (40) .
The ELISA was performed as previously described, with streptavidin-coated plates, biotinlabeled peptides, and direct binding of human p53-Abs in serum that was diluted 1:100 (with phosphate-buffered saline, pH 7.6, plus 5% nonfat dried milk) for the assay (20). The negative control employed a human serum albumin peptide (SGSGVFRRDAHKSEVAHRF), and results were expressed as the ratio between antibody binding to the p53 peptides and the control peptide. Sera were considered to be positive in this series if a ratio of 1.5 or greater was obtained, with a difference in optical density (at 450 nm) of at least 0.15 (20).
Results
Of the 80 patients with HNSCC who were tested, 15 (18.8%) possessed p53-Abs. We were able to evaluate p53 protein accumulation in 73 of the 80 tumor specimens, and accumulation was found in 43 (58.9%) of the 73 tumors. A highly significant association was found between p53 protein accumulation in tumors and the presence of p53-Abs (/ > <.001; Table 1 ).
Among the 43 tumors with p53 protein accumulation, the proportion of stained tumor nuclei was less than 15% in 10, between 15% and 85% in 24, and greater than 85% in the remaining nine. p53-Abs were found more frequently in patients with the highest proportion of p53-stained tumor nuclei (P = .008).
The distribution of the 80 patients with HNSCC according to p53-Ab status, p53 gene expression in tumors, and other histologic and clinical parameters is shown in Table 1 . A statistically significant relationship was noted between the pres-ence of p53-Abs and local-regional lymph node involvement (P = .002), whereas relationships between p53-Ab status and tumor stage and between p53-Ab status and primary tumor site did not attain statistical significance (P = .06 and P = .4, respectively; Table 1 ).
During the follow-up period, recurrent disease (local and/or distant) was evident in 32 of the 80 patients. The median time to recurrence was 10 months. The relative risks of relapse (local and distant) and the relative risks of death according to the main clinical and biologic parameters are presented in Tables 2 and 3 . In the univariate and multivariate analyses, evaluations were made with and without stratification according to the type of treatment received.
The type of treatment received and the accumulation of p53 protein in the primary tumor were not statistically sig- §p53-Abs = anti-p53 antibodies. IIModel (stepwide procedure) does not provide P values in the multivariate analysis for nodal stage, PS, and tumor stage (after stratification by treatment) because they did not reach the . 1 level. NS = not significant. nificantly related to increased risks of relapse or death in either univariate or multivariate analyses (data not shown). In the univariate analysis, higher tumor stage and the presence of p53-Abs were significantly associated with an increased risk of death (Table 2) , whereas higher tumor stage, higher nodal stage, and the presence of p53-Abs were significantly associated with an increased risk of relapse (Table 3 ). In the multivariate analysis, only higher tumor stage and the presence of p53-Abs remained significantly associated with increased risks of relapse and death (Tables 2 and 3 ).
The overall survival proportion at 2 years was 63% (95% confidence interval [CI] = 47%-80%) if no p53-Abs were detected, compared with 29% (95% CI = 4%-54%) when they were. The relapsefree survival proportion at 2 years was 62% (95% CI = 49%-76%) if no p53-Abs were detected, compared with 13% (95% CI = 0%-31%) when p53-Abs were detected (Fig. 1 ).
Discussion
Mutation of the p53 gene is one of the most common genetic alterations detected in HNSCC, and it has been shown to be associated with rapid tumor cell proliferation in this type of cancer (13). The approximately 59% frequency of p53 protein accumulation in tumors in this study is consistent with the frequencies reported in other series of HNSCC using similar techniques (4, 9, (12) (13) (14) (15) (16) 41) .
The 80 patients with HNSCC in our series were not treated in a homogeneous manner, since they were a group of consecutive patients seen over a specific period of time in our clinical department. On the other hand, this series is highly representative of the type of patients with HNSCC that we see in routine practice at our institute. The type of treatment that the patients received did not appear to be related to clinical outcome; however, to eliminate possible bias due to heterogeneity in the type of treatment, stratification was performed on this factor in both univariate and multivariate analyses.
Among the 80 patients tested, the proportion of patients with p53-Abs was low (18.8%) and very close to the 17% proportion reported by Cough et al. (32) in another series of 41 patients with HNSCC. Interestingly, Cough et al. found that p53-Abs were present in 50% of the patients with p53 mutations in their tumors, but they were not found in those lacking p53 mutations. Our results are in good agreement with those findings, since the presence of p53-Abs was almost entirely restricted to the group of tumors with p53 protein accumulation (Table 1) . The strong relationship between p53 immunostaining level and the presence of p53-Abs found in this series favors a dose-response relationship between the presence of p53-Abs and p53 protein accumulation. Accumulation of p53 protein in tumors was not significantly associated with clinical outcome, a finding similar to that reported in several other {4,13-16) but not all (12) studies. This lack of association between p53 protein accumulation and clinical outcome is in striking contrast to the strong association between the presence of p53-Abs and poor clinical outcome, despite the strong relationship between p53-Ab positivity and p53 protein accumulation. These results suggest that the humoral immune response to p53 could be a key indicator for identifying, among patients with p53 protein accumulation, those with a high probability of failure. Comparable findings have been obtained for p53-Ab positivity and breast cancer (33) but not for serum antibodies against various other tumor cell proteins and small-cell lung cancer (42) . It is clear that p53-Abs are associated with p53 gene alterations in tumors (28, 29) . However, a humoral immune response to p53 protein has been reported to occur only in a small proportion (25%-50%) of patients with tumors exhibiting cellular accumulation of p53, as shown in this and previous studies (28, 29, 33) . The mechanisms responsible for the production of p53-Abs in only a small proportion of patients with p53 protein accumulation remain to be elucidated. Davidoff et al. (22) have suggested that the type of mutation could influence the production of antibodies against p53. They showed that only p53 with mutations localized in sequences encoded by exons 5 and 6 elicited p53 antibodies, whereas mutations localized in sequences encoded by exons 7 and 8 did not. Although this observation remains to be confirmed, it is strengthened by another study (43) indicating that there are several classes of p53 mutations that can also be divided by their localization into sequences encoded by either exons 5 and 6 or exons 7 and 8. In addition, Merlo et al. (44) have shown that mutations in exons 5 and 6 are associated with a high Sphase fraction in breast cancer. Thus, it may be postulated that the presence of p53-Abs reflects p53 mutations that give rise to a more aggressive tumor phenotype.
In conclusion, p53 serum antibodies constitute a new serologic marker in patients with HNSCC. Our results strongly suggest that the detection of p53-Abs could be a means for identifying patients with a high probability of failure when treated with conventional therapies. If this association is confirmed in larger prospective studies, then it might suggest that patients with p53-Abs could be good candidates for testing new therapeutic strategies, such as gene therapy using wild-type p53.
